Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Open access

Abstract

Mosunetuzumab, a CD20×CD3 T-cell engaging bispecific antibody, redirects T cells to eliminate malignant B cells. We present updated efficacy and safety data of a pivotal phase 1/2 study after a median follow-up of 37.4 months in 90 patients with relapsed/refractory (R/R) follicular lymphoma (FL) and ≥2 prior lines of therapy treated with fixed-duration mosunetuzumab. Investigator-assessed complete response (CR) rate and objective response rate were 60.0% (95% confidence interval [CI], 49.1-70.2) and 77.8% (95% CI, 67.8-85.9), respectively. Among 70 responders, median duration of response was 35.9 months (95% CI, 20.7 to not estimable [NE]). Among 54 patients who achieved CR, 49 remained in CR at the end of treatment; median duration of CR was not reached (NR; 95% CI, 33.0 to NE); Kaplan-Meier-estimated 30-month remission rate was 72.4% (95% CI, 59.2-85.6). Estimated 36-month overall survival (OS) rate was 82.4% (95% CI, 73.8-91.0); median OS was NR (95% CI, NE to NE). Median progression-free survival was 24.0 months (95% CI, 12.0 to NE). Median time to CD19+ B-cell recovery was 18.4 months (95% CI, 12.8-25.0) after 8 cycles of mosunetuzumab treatment. No new cytokine release syndrome events or fatal, serious, or grade ≥3 adverse events were reported. With extended follow-up, mosunetuzumab demonstrated high response rates, durable remissions, and manageable safety with no long-term concerns. This supports outpatient mosunetuzumab administration as an off-the-shelf, fixed-duration, safe, and effective treatment for patients with R/R FL, including those with high-risk disease. This trial was registered at www.clinicaltrials.gov as #NCT02500407.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2024025454

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 DOR, DOCR, PFS, and OS. KM estimates showing DOR in responders (n = 70) (A), DOCR in complete responders (n = 54) by INV assessment (B), and PFS (N = 90) (C), and OS (N = 90) in the intent to treat population (D). CCOD: 2 May 2023.
Figure 1 DOR, DOCR, PFS, and OS. KM estimates showing DOR in responders (n = 70) (A), DOCR in complete responders (n = 54) by INV assessment (B), and PFS (N = 90) (C), and OS (N = 90) in the intent to treat population (D). CCOD: 2 May 2023.CC-BY-NC-ND · From the PDF
Figure 2 DOCR, PFS, and OS in patients (n = 49) with a CR at EOT. KM estimates showing DOCR (A), PFS (B), and OS (C). CCOD: 2 May 2023.
Figure 2 DOCR, PFS, and OS in patients (n = 49) with a CR at EOT. KM estimates showing DOCR (A), PFS (B), and OS (C). CCOD: 2 May 2023.CC-BY-NC-ND · From the PDF
Figure 3 Best overall response by baseline tumor mutation status. Distribution of patients by CR, PR, stable disease, or PD according to wild-type or mutational status of EZH2 , TP53 , BCL2 , CREBBP , KMT2D , and TNFRSF14 . CCOD: 2 May 2023. Mut, mutated; SD, stable disease; WT, wild-type.
Figure 3 Best overall response by baseline tumor mutation status. Distribution of patients by CR, PR, stable disease, or PD according to wild-type or mutational status of EZH2 , TP53 , BCL2 , CREBBP , KMT2D , and TNFRSF14 . CCOD: 2 May 2023. Mut, mutated; SD, stable disease; WT, wild-type.CC-BY-NC-ND · From the PDF
Figure 4 CD19 + B-cell depletion and recovery kinetics. (A) The proportion of patients and corresponding CD19 + B-cell counts in complete responders at speci fi ed time points during treatment and follow-up. The median time to B-cell recovery was de fi ned as ≥ 5 cells per μ L as determined by time to event analysis. The median time to recover to the lower level of normal was de fi ned as ≥ 70 cells per μ L. B-cell recovery from the time of last treatment cycle in patients with a CR is shown at a cutoff of ≥ 5 cells per μ L (B) and ≥ 70 cells per μ L (C). CCOD: 2 May 2023.
Figure 4 CD19 + B-cell depletion and recovery kinetics. (A) The proportion of patients and corresponding CD19 + B-cell counts in complete responders at speci fi ed time points during treatment and follow-up. The median time to B-cell recovery was de fi ned as ≥ 5 cells per μ L as determined by time to event analysis. The median time to recover to the lower level of normal was de fi ned as ≥ 70 cells per μ L. B-cell recovery from the time of last treatment cycle in patients with a CR is shown at a cutoff of ≥ 5 cells per μ L (B) and ≥ 70 cells per μ L (C). CCOD: 2 May 2023.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 2

  1. Assouline, 2024, Mosunetuzumab demonstrates clinically meaningful outcomes in high-risk patients with heavily pre-treated R/R FL after ≥3 years of follow-up: subgroup analysis of a pivotal phase II study, Hemasphere, 8, 288
  2. van de Weil, 2021, Manufacturing commercial axicabtagene ciloleucel for European patients: a 2- year retrospective analysis [abstract], Hemasphere, 5, 691

Cited by

See all 94

Metadata

Authors
Sehn, L. H., Bartlett, N. L., Matasar, M. J., Schuster, S. J., Assouline, S. E., Giri, P., Kuruvilla, J., Shadman, M., Cheah, C. Y., Dietrich, S., Fay, K., Ku, M., Nastoupil, L. J., Wei, M. C., Yin, S., To, I., Kaufman, D., Kwan, A., Penuel, E., Bolen, C. R., & Budde, L. E.
Affiliations
  • BC Cancer Agency (CA)
  • Washington University in St. Louis (US)
  • Rutgers Cancer Institute (US)
  • Abramson Cancer Center (US)
  • Jewish General Hospital (CA)
  • Royal Adelaide Hospital (AU)
  • Princess Margaret Cancer Centre (CA)
  • Fred Hutch Cancer Center (US)
  • The University of Western Australia (AU)
  • Heidelberg University (DE)
  • Royal North Shore Hospital (AU)
  • The University of Melbourne (AU)
  • The University of Texas MD Anderson Cancer Center (US)
  • Genentech (US)
  • City Of Hope National Medical Center (US)
Corresponding author
Budde, Lihua E.
Venue
Blood
Published
2025-02-13
Volume
145
Issue
7
Pages
708-719
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W4403709325
Cited by
94
References
39
Citations by year
2026: 48 · 2025: 46
FWCI
28.58
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-nd)
  • UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by-nc-nd)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
Funders
  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Gilead Sciences
  • Teva Pharmaceutical Industries
  • Celgene
  • F. Hoffmann-La Roche
  • TG Therapeutics
  • MEI Pharma
  • BeiGene
  • Incyte
  • Royal Adelaide Hospital
  • MorphoSys
  • Genentech
  • Kite Pharma
  • Pharmacyclics
  • Janssen Research and Development
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Dermatology › Cutaneous lymphoproliferative disorders research
Keywords
mosunetuzumab, relapsed/refractory follicular lymphoma, T-cell engagers, fixed-duration treatment, complete response, duration of response, overall survival, progression-free survival, B cell recovery, cytokine release syndrome, long-term safety, high-risk follicular lymphoma
MeSH terms
Antineoplastic Agents, Immunological, Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Lymphoma, Follicular, Male, Middle Aged, Neoplasm Recurrence, Local, Recurrence, Antibodies, Bispecific

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. https://app.cochat.ai/papers/10.1182/blood.2024025454
The paper
Sehn, L. H., Bartlett, N. L., Matasar, M. J., Schuster, S. J., Assouline, S. E., Giri, P., Kuruvilla, J., Shadman, M., Cheah, C. Y., Dietrich, S., Fay, K., Ku, M., Nastoupil, L. J., Wei, M. C., Yin, S., To, I., Kaufman, D., Kwan, A., Penuel, E., . . . Budde, L. E. (2025). Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood. https://doi.org/10.1182/blood.2024025454

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.